Filtered By:
Condition: Autoimmune Disease

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Transplantation of IL-1 β siRNA-modified bone marrow mesenchymal stem cells ameliorates type II collagen-induced rheumatoid arthritis in rats
Exp Ther Med. 2022 Feb;23(2):139. doi: 10.3892/etm.2021.11062. Epub 2021 Dec 14.ABSTRACTRheumatoid arthritis (RA) is a chronic autoimmune disease that causes erosion of articular cartilage and bone and has adverse effects on both patients and livestock animals. The aim of the present study was to investigate the role of interleukin-1β (IL-1β) in the pathogenesis of RA, and to further determine whether injection of IL-1β small interfering RNA (siRNA) or transplantation of IL-1β siRNA + bone marrow mesenchymal stem cells (BMSCs) can ameliorate RA in rats. A collagen-induced arthritis (CIA) rat model was established by in...
Source: Experimental and Therapeutic Medicine - January 24, 2022 Category: General Medicine Authors: Shifeng Pan Xuan Dong Yan Wang Tiansheng Zhou Yuting Liu An Zhou Hua Xing Source Type: research

Role of TRIF Small Interference RNA (siRNA) in Chronic Experimental Allergic Encephalomyelitis (EAE).
CONCLUSIONS The expression of TRIF can be down-regulated by siRNA, thereby alleviating the severity of EAE via its inhibition of interleukin and cytokine release. This may provide new insights for future treatment of MS. PMID: 26324415 [PubMed - in process]
Source: Medical Science Monitor - September 4, 2015 Category: Research Tags: Med Sci Monit Source Type: research

Lipidoid-Polymer Hybrid Nanoparticles Loaded with TNF siRNA Suppress Inflammation after Intra-articular Administration in a Murine Experimental Arthritis Model.
Abstract Rheumatoid arthritis (RA) is a common autoimmune disease, which is characterized by painful chronic inflammation in the joints, and novel safe and efficacious treatments are urgently needed. RNA interference (RNAi) therapy based on small interfering RNA (siRNA) is a promising approach for silencing specific genes involved in inflammation. However, delivery of siRNA to the target site, i.e. the cytosol of immune cells, is a challenge. Here, we designed lipid-polymer hybrid nanoparticles (LPNs) composed of lipidoid and poly(DL-lactic-co-glycolic acid) loaded with a therapeutic cargo siRNA directed against t...
Source: European Journal of Pharmaceutics and Biopharmaceutics - June 10, 2019 Category: Drugs & Pharmacology Authors: Jansen MAA, Klausen LH, Thanki K, Lyngsø J, Skov Pedersen J, Franzyk H, Nielsen HM, van Eden W, Dong M, Broere F, Foged C, Zeng X Tags: Eur J Pharm Biopharm Source Type: research

A Novel and Efficient Technology for Targeted Delivery of siRNA
The biological phenomenon of RNA interference (RNAi) has much promise for developing therapeutics to a variety of diseases. However, development of RNAi therapies remains mainly in preclinical stages largely because of difficulties in delivering small inhibitory RNAs (siRNA) and short hairpin RNAs (shRNA) into target cells. Although viral vector-based siRNA delivery systems have been widely used, their specificity and safety remains significant issue. Without a solution to this delivery problem, RNAi cannot fulfill its therapeutic promise. Investigators at the National Institutes of Health have developed novel compositions...
Source: NIH OTT Licensing Opportunities - January 1, 2009 Category: Research Authors: admin Source Type: research

Complement C2 siRNA mediated therapy of myasthenia gravis in mice.
In this study, we show that inhibition of complement cascade activation by suppressing the expression of a critical low-abundant protein, C2, in the classical complement pathway, significantly improved clinical and immunopathological manifestations of EAMG. Two weeks after a second booster immunization with acetylcholine receptor, when mice exhibit muscle weakness, i.p. injection of C2 siRNA significantly suppressed C2 mRNA in the blood cells and liver of EAMG mice. Treatment of EAMG mice with C2 siRNA, once a week for 5 weeks, significantly improved muscle strength, which was further evidenced by functional AChR preservat...
Source: Journal of Autoimmunity - February 11, 2013 Category: Allergy & Immunology Authors: Huda R, Tüzün E, Christadoss P Tags: J Autoimmun Source Type: research

Targeted Delivery of siRNA
The biological phenomenon of RNA interference (RNAi) has much promise for developing therapeutics to a variety of diseases. However, development of RNAi therapies remains mainly in preclinical stages largely because of difficulties in delivering small inhibitory RNAs (siRNA) and short hairpin RNAs (shRNA) into target cells. Although viral vector-based siRNA delivery systems have been widely used, their specificity and safety remain significant issues. Without a solution to these delivery problems, RNAi cannot fulfill its therapeutic promise.Scientists at the National Institutes of Health, National Institute on Aging have d...
Source: NIH OTT Licensing Opportunities - January 1, 2009 Category: Research Authors: ajoyprabhu3 Source Type: research

An enhanced RRM2 siRNA delivery to rheumatoid arthritis fibroblast-like synoviocytes through a liposome ‑protamine-DNA-siRNA complex with cell permeable peptides.
An enhanced RRM2 siRNA delivery to rheumatoid arthritis fibroblast-like synoviocytes through a liposome‑protamine-DNA-siRNA complex with cell permeable peptides. Int J Mol Med. 2018 Aug 08;: Authors: Wang X, Wang X, Sun J, Fu S Abstract Rheumatoid arthritis (RA) is considered to be a systemic autoimmune disease that induces systemic complications and progressive disability. It affects a large number of people. RA fibroblast‑like synoviocytes (RA‑FLS) promote the progression of RA through the secretion of proinflammatory cytokines and increasing invasiveness into the extracellular matrix. Therefo...
Source: International Journal of Molecular Medicine - August 8, 2018 Category: Molecular Biology Authors: Wang X, Wang X, Sun J, Fu S Tags: Int J Mol Med Source Type: research

Cytoplasmic Delivery of Functional siRNA Using pH-Responsive Nanoscale Hydrogels
Publication date: Available online 8 March 2019Source: International Journal of PharmaceuticsAuthor(s): William B. Liechty, Rebekah L. Scheuerle, Julia E. Vela Ramirez, Nicholas A. PeppasAbstractThe progress of short interfering RNA (siRNA) technologies has unlocked the development of novel alternatives for the treatment of a myriad of diseases, including viral infections, autoimmune disorders, or cancer. Nevertheless, the clinical use of these therapies faces significant challenges, mainly overcoming the charged and large nature of these molecules to effectively enter the cell. In this work, we developed a cationic polyme...
Source: International Journal of Pharmaceutics - March 9, 2019 Category: Drugs & Pharmacology Source Type: research

Transdermal Delivery of Adipocyte Phospholipase A2 siRNA using Microneedles to Treat Thyroid Associated Ophthalmopathy-Related Proptosis
This study sets the stage not only for future treatment of TAO-related proptosis using AdPLA siRNA, but also provides the foundation for targeted siRNA delivery by using microneedles.PMID:33880967 | DOI:10.1177/09636897211010633
Source: Cell Transplantation - April 21, 2021 Category: Cytology Authors: Guiqin Liu Yan Deng Yi Song Yi Sui Juan Cen Ziyu Shao Hu Li Tao Tang Source Type: research